

1 **Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2**

2

3 Dami A. Collier<sup>1,2,3\*</sup>, Isabella A.T.M. Ferreira<sup>\*1,2</sup>, Prasanti Kotagiri<sup>1,2\*</sup>, Rawlings Datir<sup>\* 1,2,3</sup>,  
4 Eleanor Lim<sup>2\*</sup>, Emma Touzier<sup>3</sup>, Bo Meng<sup>1,2</sup>, Adam Abdullahi<sup>1</sup>, The CITIID-NIHR  
5 BioResource COVID-19 Collaboration<sup>3</sup>, Anne Elmer<sup>4</sup>, Nathalie Kingston<sup>5</sup>, Barbara Graves<sup>5</sup>,  
6 Emma Le Gresley<sup>5</sup>, Daniela Caputo<sup>5</sup>, Kenneth GC Smith<sup>1,2</sup>, John R. Bradley<sup>2,5</sup>, Lourdes  
7 Ceron-Gutierrez<sup>6</sup>, Paulina Cortes-Acevedo<sup>7</sup>, Gabriela Barcenas-Morales<sup>7</sup>, Michelle  
8 Linterman<sup>8</sup>, Laura McCoy<sup>3</sup>, Chris Davis<sup>9</sup>, Emma Thomson<sup>9</sup>, Paul A. Lyons<sup>1,2</sup>, Eoin  
9 McKinney<sup>1,2</sup>, Rainer Doffinger<sup>6</sup>, Mark Wills<sup>1,2</sup>, Ravindra K. Gupta<sup>1,2</sup>

10

11 <sup>1</sup>Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.

12 <sup>2</sup>Department of Medicine, University of Cambridge, Cambridge, UK.

13 <sup>3</sup>Division of Infection and Immunity, University College London, London, UK.

14 <sup>4</sup>The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix 1 for author list

15 <sup>5</sup>NIHR Cambridge Clinical Research Facility, Cambridge, UK.

16 <sup>6</sup>Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK

17 <sup>7</sup>Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico

18 <sup>8</sup>Babraham Institute, Cambridge, UK

19

20

21 **Correspondence to:**

22 Ravindra K. Gupta

23 Cambridge Institute of Therapeutic Immunology and Infectious Diseases

24 Jeffrey Cheah Biomedical Centre

25 Cambridge Biomedical Campus

26 Puddicombe Way

27 Cambridge CB2 0AW

28 Tel: 441223331491 [rkg20@cam.ac.uk](mailto:rkg20@cam.ac.uk)

29 Or

30 Mark Wills

31 Department of Medicine

32 Level 5 Addenbrookes Hospital

33 Cambridge, CB20QQ

34 Tel: 441223 336862 [mrw1004@cam.ac.uk](mailto:mrw1004@cam.ac.uk)

35 Or

36 Rainer Doffinger

37 Department of Clinical Biochemistry and Immunology

38 Addenbrookes Hospital

39 Cambridge, CB20QQ

40 [rd270@medschl.cam.ac.uk](mailto:rd270@medschl.cam.ac.uk)

41 **Key words: SARS-CoV-2; COVID-19; immune response; vaccine; neutralising**  
42 **antibodies, T cell, B cell repertoire.**

43

44

45 **Abstract**

46 Two dose mRNA vaccination provides excellent protection against SARS-CoV-2. However,  
47 there are few data on vaccine efficacy in elderly individuals above the age of 80<sup>1</sup>.

48 Additionally, new variants of concern (VOC) with reduced sensitivity to neutralising  
49 antibodies have raised fears for vulnerable groups. Here we assessed humoral and cellular  
50 immune responses following vaccination with mRNA vaccine BNT162b2<sup>2</sup> in elderly  
51 participants prospectively recruited from the community and younger health care workers.  
52 Median age was 72 years and 51% were females amongst 140 participants. Neutralising  
53 antibody responses after the first vaccine dose diminished with increasing age, with a marked  
54 drop in participants over 80 years old. Sera from participants below and above 80 showed  
55 significantly lower neutralisation potency against B.1.1.7, B.1.351 and P.1. variants of  
56 concern as compared to wild type. Those over 80 were more likely to lack any neutralisation  
57 against VOC compared to younger participants following first dose. The adjusted odds ratio  
58 for inadequate neutralisation activity against the B.1.1.7, P.1 and B.1.351 variant in the older  
59 versus younger age group was 4.3 (95% CI 2.0-9.3, p<0.001), 6.7 (95% CI 1.7- 26.3,  
60 p=0.008) and 1.7 (95% CI 0.5-5.7, p=0.41). Binding IgG and IgA antibodies were lower in  
61 the elderly, as was the frequency of SARS-CoV-2 Spike specific B-memory cells. We  
62 observed a trend towards lower somatic hypermutation in participants with suboptimal  
63 neutralisation, and elderly participants demonstrated clear reduction in class switched somatic  
64 hypermutation, driven by the IgA1/2 isotype. SARS-CoV-2 Spike specific T- cell IFN $\gamma$  and  
65 IL-2 responses fell with increasing age, and both cytokines were secreted primarily by CD4 T  
66 cells. We conclude that the elderly are a high risk population that warrant specific measures  
67 in order to mitigate against vaccine failure, particularly where variants of concern are  
68 circulating.

69

## 70 **Background**

71 Vaccines designed to elicit protective immune responses remain the key hope for containing  
72 the SARS-CoV-2 pandemic. In particular, mRNA vaccines have shown excellent efficacy  
73 using a two-dose approach, separated by a three or four week gap<sup>2,3</sup>. Although data on  
74 neutralising responses as a correlate of protection are increasing<sup>4,5</sup>, few data on neutralising  
75 responses or vaccine efficacy in elderly individuals above the age of 80 are available in trial  
76 settings<sup>1</sup>. This is even more pertinent for settings where a dosing interval of 12-16 weeks or  
77 even more has been implemented to maximise first dose administration<sup>6</sup>. In the absence of  
78 adequate clinical trial data, ‘real world’ data on vaccine responses are vital in order to  
79 understand the likely efficacy of vaccination using this dosing regime in those who are at  
80 greatest risk of severe disease and death<sup>7</sup>.

81

82 Additionally, the emergence of new variants with increased transmissibility<sup>8</sup>, reduced  
83 sensitivity to vaccine elicited antibodies<sup>9</sup> and reduced clinical efficacy in preventing  
84 infection<sup>10</sup> has raised fears for vulnerable groups where magnitude and quality of immune  
85 responses may be suboptimal. Here we assessed humoral and cellular immune responses  
86 following vaccination with mRNA-based vaccine BNT162b2<sup>2</sup> in unselected elderly  
87 participants from the community and younger health care workers.

88

## 89 **Results**

### 90 **Neutralisation of SARS-CoV-2 following mRNA vaccination in the elderly**

91 One hundred and forty participants received at least one vaccination, with median age 72  
92 years (IQR 44-83) and 51% of participants female (Extended Data Figure 1). We first  
93 validated the use of a pseudotyped virus (PV) system to investigate neutralisation, by  
94 comparing geometric mean titres (GMT) between PV expressing Wuhan-1 D614G spike and  
95 a B.1 lineage live virus isolate, using sera isolated from thirteen individuals after two vaccine  
96 doses (Extended data Figure 2a). We observed high correlation between the two approaches,  
97 consistent with previous literature<sup>11</sup>, and therefore proceeded with the PV system.

98

99 We explored the association between age and ability to neutralise virus by plotting the  
100 proportion of individuals who had detectable virus neutralisation after the first dose at a given  
101 age. This analysis showed a non-linear relationship with marked drop around the age of 80  
102 (Figure 1a). Given this observation of a non-linear change in a correlate of protection we  
103 performed selected subsequent analyses with age both as a continuous variable and as a

104 categorical variable. When individuals 80 years and above were tested between 3 and 12  
105 weeks post first dose, around half had no evidence of neutralisation (Extended data Figure  
106 2b). GMT was lower in participants 80 years and older than in younger individuals [48.2  
107 (95% CI 34.6-67.1) vs 104.1 (95% CI 69.7-155.2)  $p < 0.0001$  Table 1, Figure 1b]. Geometric  
108 mean neutralisation titre (GMT) after the first dose (but not second dose) showed evidence of  
109 a modest inverse association with age (Extended data Figure 2c). The duration of the interval  
110 between first and second dose (three versus twelve weeks) did not appear to impact GMT  
111 following the second dose, though numbers were limited (Extended data Figure 2d). There  
112 was evidence for prior COVID-19 infection in 5 individuals in each group using a clinically  
113 accredited assay for N antibodies<sup>9</sup> (Table 1), and this was adjusted for in multivariable  
114 analyses (Table 2, Supplementary Table 1). Sera from vaccinated individuals exhibited an  
115 increase in neutralising titres between the first and second doses for individuals both below  
116 and above the age of 80 years (Figure 1b). In those participants with suboptimal or no  
117 neutralisation who received second doses within the study period (examples shown in Figure  
118 1c), testing after the second dose showed that all responded (Table 1 and Figure 1b).

119

### 120 **Neutralisation of SARS-CoV-2 variants of concern by vaccine elicited sera in the elderly**

121 Given our observation that the participants 80 years old and older had lower neutralisation  
122 responses following first dose, we hypothesised that this could lead to sub protective  
123 neutralising responses against B.1.1.7, B.1.351 and P.1 variants of concern (VOC),  
124 originating in UK, South Africa and Brazil respectively (Figure 1d). We therefore examined  
125 serum neutralisation by age group against PV bearing WT or the three VOC spike proteins  
126 (Figure 1e, f). There was a clear reduction in neutralising titres against VOC as previously  
127 noted (Figure 1e), with the over 80 year olds exhibiting lower titres than younger individuals  
128 for all except B.1.351 where neutralisation was very poor universally following the first dose.  
129 When we analysed the proportions of individuals with no detectable neutralisation we  
130 observed the same pattern (Figure 1f). The adjusted odds ratio for achieving inadequate  
131 neutralisation against WT was 3.7 (95% CI 1.7-8.1,  $p = 0.001$ ) for participants 80 years and  
132 older versus those younger than 80 years (Table 2). The adjusted odds ratio for inadequate  
133 neutralisation activity against the B.1.1.7, P.1 and B.1.351 variant in the older versus younger  
134 age group was 4.3 (95% CI 2.0-9.3,  $p < 0.001$ ), 6.7 (95% CI 1.7- 26.3,  $p = 0.008$ ) and 1.7 (95%  
135 CI 0.5-5.7,  $p = 0.41$ ) respectively (Table 2 and Supplementary Table 1).

136

### 137 **Binding Antibody responses and B cell Repertoire Analyses**

138 Binding antibody responses to full length WT Wuhan-1 Spike were comprehensively  
139 measured using a clinically accredited particle based assay that we have previously  
140 described<sup>9</sup>. IgG and all IgG subclasses against Spike increased between vaccine doses (Figure  
141 2a), reaching levels after the second dose similar to those observed following natural  
142 infection. IgG against Spike declined with age mirroring the neutralisation titres (Figure 2b,  
143 Extended Data Figure 3a). The concentration of total and subclass anti-Spike IgGs were  
144 significantly lower in the 80 years and older age group (Figure 2c). IgG and subclasses  
145 showed correlation with neutralisation (Figure 2c and Extended Data Figure 3b). IgA  
146 responses were detected both in convalescent sera (from individuals hospitalised in early-mid  
147 2020) and after both doses, with an increase between the two time points (Extended Data  
148 Figure 3c). Spike specific IgA also correlated with neutralisation after dose 1(Extended Data  
149 Figure 3d). In addition, PBMC phenotyping by flow cytometry revealed neutralisation in the  
150 over 80 age group was associated with higher proportion of spike specific IgG+ IgM- CD19+  
151 B memory cells (Figure 3e). Interestingly this did not differentiate neutralisers from non-  
152 neutralisers in the under 80 group (Figure 3e, Extended Data Figure 4b).

153  
154 Next B cell Repertoire (BCR) sequencing on bulk PBMCs was performed to assess isotype  
155 and variable gene usage, somatic hypermutation and diversity of the repertoire between the  
156 two age groups and in relation to neutralisation. All patients analysed had been vaccinated at  
157 a minimum 17 days prior. After correcting for multiple comparisons, there were no  
158 differences in isotype proportions between the two age groups (Extended Data Figure 5), or  
159 by neutralisation (Figure 3a). We next looked for skewing in V gene use (Figure 3b). We  
160 found an increase in usage of the IGHV4 family in the older age group with an increased  
161 proportion of IGHV4.34, IGHV4.39, IGHV4.59 and IGHV4.61 whilst in the younger age  
162 group there was an increase in usage of the IGHV1 family with increases in IGHV1.18 and  
163 IGHV1.69D. We did not find any significant differences in V gene usage with neutralisation  
164 (Extended Data Figure 5).

165  
166 Differences in somatic hypermutation could impact neutralisation through antibody affinity  
167 maturation. We found that participants 80 years or older had a lower level of somatic  
168 hypermutation compared with the under 80 year olds in class-switched BCRs, which was  
169 driven by the IgA1/2 isotype (Figure 3c). There appeared to be a correlation between IC50  
170 and degree of somatic hypermutation in class-switched BCRs (Figure 3d) driven  
171 predominantly by IGHA (Figure 3e). We did not observe a relationship between titres of IgG

172 and mutation in BCRs for IgG1/2 (Extended Data Figure 5). To assess whether there  
173 was greater clonal expansion in those younger than 80 years old that might explain higher  
174 neutralising responses, we calculated richness, using the Chao1 measure and diversity  
175 using D50, Simpson's and Shannon-weiner indices. We did not find any significant  
176 differences between age groups or a relationship between measures of diversity and  
177 neutralisation potency (Figure 3f, Extended Data Figure 5).

178

179 We next examined the BCR for public clones known to be associated with SARS-CoV-2  
180 neutralisation. We explored the convergence between BCR clones present in our study with  
181 the CoV-AbDab database, a resource detailing all published antibodies shown to bind SARS-  
182 CoV-2<sup>12</sup>. Convergent clones were annotated with the same IGHV and IGHJ segments, had  
183 the same CDR-H3 region length and were clustered based on 85% CDR-H3 sequence amino  
184 acid homology. A cluster was considered convergent with the CoV-AbDab database if it  
185 contained sequences from post-vaccinated individuals and from the database. This analysis  
186 revealed that participants under 80 had a higher frequency of convergent clones in keeping  
187 with increased neutralization when compared with the >80 age group (Figure 3g).

188

### 189 **T cell responses to SARS-CoV-2 spike following mRNA vaccination**

190 Whilst neutralising antibodies are increasingly recognised as dominating protection against  
191 initial infection<sup>4,13</sup>, T cells may also play a role where neutralising antibody titres are low<sup>14</sup>,  
192 possibly limiting disease progression<sup>5</sup>. We therefore determined the T cell response to SARS-  
193 CoV-2 spike protein in vaccinees by stimulating PBMC with overlapping peptide pools to the  
194 wild type SARS-CoV-2 spike, using IFN $\gamma$  and IL-2 FluoroSpot assay to enumerate spike  
195 specific T cells. With the same peptide pool, we also stimulated i. PBMC that had been  
196 collected and biobanked between 2014-2016 - representing a healthy SARS-CoV-2  
197 unexposed population to provide a background control, ii. PBMC from donors who had RT-  
198 PCR confirmed infection with SARS-CoV-2 for a comparison of T cell responses following  
199 natural infection. When we plotted IFN $\gamma$  spike specific T cell responses against age as a  
200 continuous variable there was a negative correlation and drop off at around 80 years (Figure  
201 4a). A similar though less pronounced effect was seen for IL-2 (Figure 4b). However, there  
202 did not appear to be a relationship between cytokine production by PBMC and neutralisation  
203 titre following first dose (Extended Data Figure 6).

204

205 Following the first dose of vaccine, the frequency of IFN $\gamma$  secreting T cells against a peptide  
206 pool including Cytomegalovirus, EBV and Flu (CEF+) specific peptides did not differ by age  
207 category and was similar to healthy SARS-CoV-2 unexposed controls (Figure 4c).

208 This indicates that differences in observed responses were likely vaccine specific and  
209 unlikely due to generalised suboptimal T cell responses/immune paresis. However, IFN $\gamma$   
210 spike specific T cell responses were significantly larger than responses observed in an  
211 unexposed population for individuals under 80 (Figure 4d). Importantly however, in the 80  
212 years and older participants, the IFN $\gamma$  spike specific T cell responses were not different from  
213 the unexposed controls following first dose (Figure 4d). By contrast, spike specific IL-2 T  
214 cell frequencies were significantly greater than unexposed control in both age groups (Figure  
215 4e). Interestingly, it appeared that whilst spike specific IFN $\gamma$  and IL2 responses in PBMC  
216 were similar to those found after natural infection (Figure 4f,g), the second dose did not  
217 increase these responses, either overall (Figure 4f,g) or within age categories (Figure 4h,i).

218

219 We separated T cell subsets to further clarify the cells producing IFN $\gamma$  and IL-2. PBMC from  
220 a sample of individuals <80 years and >80 years were depleted of CD4 or CD8 T cells and  
221 stimulated with spike peptide pool as before. Our results showed that the majority of IFN $\gamma$   
222 and IL-2 production was from the CD4+ T cells in vaccinated individuals (Figure 4j,k). The  
223 over 80 year olds had markedly lower spike specific IL2 CD4 T cell responses than their  
224 younger counterparts (Figure 4i).

225

226 CMV serostatus has been associated with poorer responses to vaccination and infections<sup>15,16</sup>  
227 and we hypothesised that older individuals were more likely to be CMV positive and  
228 therefore poorer associated T cell responses to mRNA vaccination. We therefore ascertained  
229 CMV serostatus by ELISA testing and related this to T cell responses and serum  
230 neutralisation. As expected, CMV IgG positivity was higher in the 80 years and older age  
231 group (Extended Data Figure 7). Surprisingly however, CMV positive individuals in the 80  
232 years and older group had significantly higher IFN $\gamma$ , but not IL2, responses to SARS-CoV-2  
233 spike peptides compared to the under 80 year old group (Extended Data Figure 7).

234

### 235 **Autoantibodies and inflammatory chemo/cytokines and responses to mRNA vaccination**

236 Finally, we investigated possible interplay between senescence and mRNA vaccine responses.

237 Autoantibodies and inflammatory cyto/chemokines are associated with immune senescence<sup>17</sup>.

238 We first measured a panel of autoantibodies in the sera of 101 participants following the first  
239 dose of the BNT162b2 vaccine. 8 participants had positive autoantibodies for anti-  
240 myeloperoxidase (anti-MPO), 2 for anti-fibrillarlin and 1 for anti-cardiolipin antibodies  
241 (Extended Data Figure 8). As expected, all but one of the participants with anti-  
242 myeloperoxidase autoantibody was over the age of 80 years (Extended Data Figure 8). There  
243 was a trend towards reduced anti-Spike IgG levels and serum neutralisation against wild type  
244 and B.1.17 Spike mutant in participants with positive autoantibodies, although this did not reach  
245 statistical significance, likely due to small numbers (Extended Data Figure 8). Next, we  
246 explored the association between serum cytokines/chemokines and neutralisation of SARS-  
247 CoV-2 PV as well as their association with age. P1DF, a known SASP (senescence associated  
248 secretory phenotype) molecule was the only molecule enriched in sera from participants over  
249 80 years, and there was no association between any of these molecules and ability of sera to  
250 neutralise SARS-CoV-2 PV (Extended Data Figure 8).

251

252

## 253 **Discussion**

254 Immune senescence is a well described phenomenon whereby responses to pathogens<sup>18</sup> and  
255 indeed vaccines are impaired/dysregulated with age<sup>19</sup>. As an example, effective seasonal  
256 influenza vaccination of the elderly is a significant public health challenge due to greater  
257 morbidity and mortality in this group. Lower neutralizing antibody titres using standard dose  
258 influenza vaccines in elderly individuals has been addressed by using higher dose vaccine,  
259 highlighting that understanding of age related heterogeneity in vaccine responses can lead to  
260 policy change and mitigation <sup>20</sup>.

261

262 Neutralising antibodies are likely the strongest correlate of protection from SARS-CoV-2  
263 infection, as shown by vaccine efficacy studies, animal studies in mice and non-human  
264 primates, and data from early use of convalescent plasma in elderly patients <sup>4,5,13,14,21,22</sup>.

265 There is a lack of data on neutralising antibody immune responses following mRNA  
266 vaccination in the elderly and no data on variants of concern in this group. In a clinical study  
267 specifically looking at older adults vaccinated with BNT162b2 the GMT (geometric mean  
268 titre) after first dose was 12 in a set of 12 subjects between ages of 65 and 85 years, rising to  
269 149 seven days after the second dose <sup>1</sup>. Furthermore, in the Moderna 1273 mRNA vaccine  
270 study in older individuals (above 55 years), neutralisation was only detectable after the  
271 second dose, whilst binding antibodies were detectable after both doses<sup>23</sup>. In a randomised



272 phase 1 study on BNT162b1 in younger (18-55) and older adults (65-85), Li et al observed  
273 lower virus neutralisation in the older age group at day 22 post first dose <sup>24</sup>. These data  
274 parallel those in aged mice where ChAdOx nCov-19 vaccine responses were reported as  
275 being lower as compared to younger mice, and this was overcome by booster dosing<sup>25</sup>.

276

277 Here, in a substantial cohort of 140 individuals, we have shown not only an inverse  
278 relationship between age and neutralising responses following first dose of BNT162b2, but a  
279 more precipitous decline around the age of 80. Individuals 80 and above were prioritised for  
280 vaccination in the UK and elsewhere as they represented the group at greatest risk of severe  
281 COVID-19<sup>26</sup>. We found that around half of those above the age of 80 have a suboptimal  
282 neutralising antibody response after first dose vaccination with BNT162b2, accompanied by  
283 lower T cell responses compared to younger individuals. Individuals over 80 differed in four  
284 main respects that could explain poorer neutralisation of SARS-CoV-2. Firstly, serum IgG  
285 levels were lower, accompanied by a lower proportion of peripheral spike specific IgG+ IgM-  
286 CD19+ B memory cells. Secondly, the elderly displayed lower SHM in the BCR gene.  
287 Thirdly, the elderly had lower enrichment for public BCR clonotypes that are associated with  
288 neutralisation. Fourthly, the elderly displayed a marked reduction in IL-2 producing spike  
289 reactive CD4 T cells. Therefore possible explanations for poorer neutralising responses  
290 include lower concentrations (quantity) and/or lower affinity antibodies (quality) due to B  
291 cell selection, CD4 T cell help, or a combination of both.

292

293 Critically, we show that elderly individuals are likely at greater risk from VOC. When  
294 B.1.1.7 and P.1 variant spike PV were tested against sera in this study, a greater proportion of  
295 individuals in the over 80 age group lost all neutralising activity following first dose as  
296 compared to the wild type. As expected, B.1.351, known to have the highest degree of  
297 resistance to NAb<sup>27</sup>, did not appear to have preferential impact on the elderly after one dose,  
298 because sera from all ages had poor activity. The lack of neutralising activity against VOC  
299 following first dose in the elderly is of great concern in the current climate where variants are  
300 expanding globally and countries are struggling to acquire adequate vaccine supplies to  
301 ensure timely administration of both doses. We observed robust neutralising responses across  
302 all age groups after the second dose.

303

304 Following the second dose, binding IgG and IgA antibodies to Spike increased, mirroring  
305 levels seen in natural infection. Consistent with these data, the UK REACT study, a large,

306 observational community based study, has shown that the prevalence of IgG positivity was  
307 34.7% 21 days after the first dose of BNT162b2 in those over 80 years, increasing to 87.8%  
308 after the second dose<sup>28</sup>.

309

310 Although neutralising antibody responses appear critical, studies in rhesus macaques also  
311 show that CD8 T cells may play a role in contributing to protection from SARS-CoV-2  
312 disease when neutralising antibody levels are low<sup>14</sup>. We speculate that this may explain why  
313 recent observational studies have demonstrated some effect against hospitalisation after 1  
314 dose of the BNT162b2 or ChAdOx1nCoV-19 in the context of VOC<sup>10,29-32</sup>. SARS-CoV-2  
315 infection generates robust T cell responses to spike protein in the majority of individuals  
316 post infection. The IL2 response is predominantly produced by CD4+ T cells and that IFN $\gamma$   
317 production was seen in both spike specific CD4 and CD8+ T cell subsets<sup>33,34</sup>. By contrast,  
318 and in agreement with Anderson et al for the 1273 mRNA vaccine<sup>23</sup>, we found that spike  
319 specific IFN $\gamma$  and IL-2 T cell responses to BNT162b2 mRNA vaccine were largely CD4 T  
320 cell derived. Phase I/II clinical trials of adenovirus vectored SARS-COV-2 vaccines have  
321 similarly showed a Th1 skewed response with elevated TNF $\alpha$ , IL2 and IFN $\gamma$  being secreted  
322 by both CD4+ and CD8+ T cells<sup>23,35-38</sup>.

323

324 We found that both IFN $\gamma$  and IL-2 PBMC responses were significantly lower in the over 80  
325 age group and did not increase after the second dose, similar to findings for ChAdOx1<sup>39</sup>.  
326 Parry et al also reported suboptimal IFN  $\gamma$  responses in over 80 year olds following two doses  
327 of BNT162b2 (<https://dx.doi.org/10.2139/ssrn.3816840>). In particular it appeared that lower  
328 IL2 responses in PBMC may reflect very low spike specific CD4 IL2 responses in the over  
329 80 age group.

330

331 SARS CoV-2 mRNA vaccination has been shown to generate potent T<sub>FH</sub> and GC responses,  
332 correlating with neutralisation<sup>40</sup>. Interactions between B-cells and T follicular helper (T<sub>FH</sub>) in  
333 the germinal centre (GC) are needed for long-lived memory B cells/ plasma cells and high-  
334 affinity, class-switched antibodies<sup>41,42</sup>. In our B cell repertoire analyses we explored  
335 correlates for the impaired virus neutralisation by antibodies observed in a high proportion of  
336 older individuals. We found that participants >80 had a lower mean somatic hypermutation in  
337 class-switched BCRs, driven by the IgA1/2 isotype. There was a trend towards significant  
338 correlation between IC50 and somatic hypermutation in class-switched and in IGHA BCR.

339 Our data hint towards a mechanism whereby impaired T cell responses, as indicated by our  
340 data showing lower SARS-CoV-2 spike induced T cell cytokine production in the elderly,  
341 could impair generation of high affinity, class-switched, potentially neutralising antibodies. In  
342 addition the lack of public BRC clones associated with neutralising antibodies in the elderly  
343 may relate to altered selection of B cell clones.

344

### 345 **Conclusion**

346 *In vitro* virus neutralisation is increasingly recognised as the most significant correlate of  
347 protection from SARS-CoV-2 infection<sup>4,5,13,14</sup>. Whilst significant public health impact of  
348 vaccines is anticipated, and indeed has been demonstrated<sup>43</sup>, a significant proportion of  
349 individuals above 80 appear to require the second dose to achieve virus neutralisation and are  
350 disproportionately vulnerable to SARS-CoV-2 variants after the first dose. Our data caution  
351 against extending the dosing interval of BNT162b2 in the elderly population, particularly  
352 during periods of high transmission and risk from variants that are less susceptible to  
353 vaccine-elicited neutralising antibodies<sup>44-47</sup>. The mechanism of reduced neutralising  
354 responses in the elderly needs to be further delineated in order to inform mitigation strategies.

355

### 356 **Acknowledgements**

357 We would like to thank Cambridge University Hospitals NHS Trust Occupational Health  
358 Department. We would also like to thank the NIHR Cambridge Clinical Research Facility and  
359 staff at CUH, the Cambridge NIHR BRC Stratified Medicine Core Laboratory NGS Hub, the  
360 NIHR Cambridge BRC Phenotyping Hub, Petra Mlcochova, Steven A. Kemp, Martin Potts,  
361 Ben Krishna, Marianne Perera and Georgina Okecha. We would like to thank James Nathan,  
362 Leo James and John Briggs. RKG is supported by a Wellcome Trust Senior Fellowship in  
363 Clinical Science (WT108082AIA). DAC is supported by a Wellcome Trust Clinical PhD  
364 Research Fellowship. KGCS is the recipient of a Wellcome Investigator Award  
365 (200871/Z/16/Z). This research was supported by the National Institute for Health Research  
366 (NIHR) Cambridge Biomedical Research Centre, the Cambridge Clinical Trials Unit (CCTU),  
367 the NIHR BioResource and Addenbrooke's Charitable Trust, the Evelyn Trust (20/75), UKRI  
368 COVID Immunology Consortium. GBM and PCA were supported by UNAM-FESC-PIAPI  
369 Program Code PIAPI2009 and by CONACyT 829997 fellowship. The views expressed are  
370 those of the authors and not necessarily those of the NIHR or the Department of Health and  
371 Social Care. IATMF is funded by a Sub-Saharan African Network for TB/HIV Research

372 Excellence (SANTHE, a DELTAS Africa Initiative (grant DEL-15-006)) fellowship. We  
373 would like to thank Davide Corti for the VOC plasmids.

374  
375  
376

## 377 **Methods**

### 378 *Study Design*

379 Community participants or health care workers receiving the first dose of the BNT162b2  
380 vaccine between the 14<sup>th</sup> of December 2020 to the 10<sup>th</sup> of February 2021 were consecutively  
381 recruited at Addenbrookes Hospital into the COVID-19 cohort of the NIHR Bioresource.  
382 Participants were followed up for up to 3 weeks after receiving their second dose of the  
383 BNT162b2 vaccine. They provided blood samples 3 to 12 weeks after their first dose and again  
384 3 weeks after the second dose of the vaccine. Consecutive participants were eligible without  
385 exclusion. The exposure of interest was age, categorised into 2 exposure levels-  $< 80$  and  $\geq 80$   
386 years. The outcome of interest was inadequate vaccine-elicited serum antibody neutralisation  
387 activity at least 3 weeks after the first dose. This was measured as the dilution of serum required  
388 to inhibit infection by 50% (ID50) in an *in vitro* neutralisation assay. An ID50 of 20 or below  
389 was deemed as inadequate neutralisation. Binding antibody responses to Spike, Receptor  
390 binding domain and Nucleocapsid were measured by multiplex particle-based flow cytometry  
391 and Spike-specific T cell responses were measured by IFN $\gamma$  and IL-2 FLUOROSPOT assays.  
392 Measurement of serum autoantibodies and characterisation of the B cell receptor repertoire  
393 (BCR) following the first vaccine dose were exploratory outcomes.

394

395 We assumed a risk ratio of non-neutralisation in the  $\geq 80$  years group compared with  $< 80$  years  
396 group of 5. Using an alpha of 0.05 and power of 90% required a sample size of 50 with a 1:1  
397 ratio in each group.

398

### 399 *Ethical approval*

400 The study was approved by the East of England – Cambridge Central Research Ethics  
401 Committee (17/EE/0025). PBMC from unexposed volunteers previously recruited by the  
402 NIHR BioResource Centre Cambridge through the ARIA study (2014-2016), with ethical  
403 approval from the Cambridge Human Biology Research Ethics Committee  
404 (HBREC.2014.07) and currently North of Scotland Research Ethics Committee 1  
405 (NS/17/0110).

406

## 407 *Statistical Analyses*

408 Descriptive analyses of demographic and clinical data are presented as median and interquartile  
409 range (IQR) when continuous and as frequency and proportion (%) when categorical. The  
410 difference in continuous and categorical data were tested using Wilcoxon rank sum and Chi-  
411 square test respectively. Logistic regression was used to model the association between age  
412 group and neutralisation by vaccine-elicited antibodies after the first dose of the BNT162b2  
413 vaccine. The effect of sex and time interval from vaccination to sampling as confounders were  
414 adjusted for. Linear regression was also used to explore the association between age as a  
415 continuous variable and log transformed ID50, binding antibody levels, antibody subclass  
416 levels and T cell response after dose 1 and dose 2 of the BNT162b2 vaccine. The time interval  
417 from vaccination to sampling was adjusted for. Bonferroni adjustment was made for multiple  
418 comparisons in the linear correlation analyses between binding antibody levels, ID50, age and  
419 T cell responses. The Pearson's correlation coefficient for linear data and Spearman's  
420 correlation for non-linear data was reported. Statistical analyses were done using Stata v13,  
421 Prism v9 and R (version 3.5.1).

422

## 423 *Generation of Mutants and pseudotyped viruses*

424 Wild-type (WT) bearing 614G and B.1.1.7 bearing mutations del-69/70, del-144,  
425 N501Y, A570D, D614G, P681H, S982A, T716I and D1118H or K417N, E484K and N501Y  
426 pseudotyped viruses were generated as previously described<sup>44</sup>. In brief, amino acid substitutions  
427 were introduced into the D614G pCDNA\_SARS-CoV-2\_S plasmid as previously described<sup>48</sup>  
428 using the QuikChange Lightning Site-Directed Mutagenesis kit, following the manufacturer's  
429 instructions (Agilent Technologies, Inc., Santa Clara, CA). Sequences were verified by Sanger  
430 sequencing. The pseudoviruses were generated in a triple plasmid transfection system whereby  
431 the Spike expressing plasmid along with a lentiviral packaging vector- p8.9 and luciferase  
432 expression vector- psCSFLW where transfected into 293T cells with Fugene HD transfection  
433 reagent (Promega). The viruses were harvested after 48 hours and stored at -80oC. TCID50 was  
434 determined by titration of the viruses on 293Ts expressing ACE-2 and TMPRSS2.

435

## 436 *Pseudotyped virus neutralisation assays*

437 Spike pseudotype assays have been shown to have similar characteristics as neutralisation  
438 testing using fully infectious wild type SARS-CoV-2<sup>11</sup>. Virus neutralisation assays were  
439 performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2  
440 Spike pseudotyped virus expressing luciferase<sup>49</sup>. Pseudotyped virus was incubated with serial

441 dilution of heat inactivated human serum samples or sera from vaccinees in duplicate for 1h at  
442 37°C. Virus and cell only controls were also included. Then, freshly trypsinized 293T  
443 ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a 5%  
444 CO<sub>2</sub> environment at 37°C, luminescence was measured using the Steady-Glo Luciferase assay  
445 system (Promega). Neutralization was calculated relative to virus only controls. Dilution curves  
446 were presented as a mean neutralization with standard error of the mean (SEM). 50%  
447 neutralization- ID50 values were calculated in GraphPad Prism. The limit of detection for 50%  
448 neutralisation was set at an ID50 of 20. The ID50 within groups were summarised as a  
449 geometric mean titre (GMT) and statistical comparison between groups were made with Mann-  
450 Whitney or Wilcoxon ranked sign test.

451

#### 452 *Live virus serum neutralisation assays*

453 A549-Ace2-TMPRSS2 cells were seeded at a cell density of  $2.4 \times 10^4$ /well in a 96 well plate  
454 24hrs before inoculation. Serum was titrated starting at a final 1:50 dilution with live B.1  
455 virus PHE2 (EPI\_ISL\_407073) isolate being added at an MOI 0.01. The mixture was then  
456 incubating for 1hr prior to adding to the cells. 72hrs post infection the plates were fixed with  
457 8% formaldehyde then stained with Coomassie blue for 30 minutes. The plates were washed  
458 and dried overnight before using a Celigo Imaging Cytometer (Nexcelom) to measure the  
459 staining intensity. Percentage cell survival was determined by comparing the intensity of the  
460 staining to an uninfected well. A non-linear sigmoidal 4PL model (Graphpad Prism 9) was  
461 used to determine the IC50 for each serum. The correlation between log transformed ID50  
462 obtained from the pseudotyped virus and live virus systems were explored using linear  
463 regression. Pearson's correlation coefficient was determined.

464

465

#### 466 *SARS-CoV-2 serology by multiplex particle-based flow cytometry (Luminex):*

467 Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to distinct carboxylated  
468 bead sets (Luminex; Netherlands) to form a 3-plex and analyzed as previously described<sup>50</sup>.  
469 Specific binding was reported as mean fluorescence intensities (MFI).

470

#### 471 *CMV serology:*

472 HCMV IgG levels determined using an IgG enzyme-linked immunosorbent (EIA) assay,  
473 HCMV Captia (Trinity Biotech, Didcot, UK) following manufacturer's instructions, on  
474 plasma derived from clotted blood samples.

475

476 *Serum autoantibodies:*

477 Serum was screened for the presence of autoantibodies using the ProtoPlex™ autoimmune  
478 panel (Life Technologies) according to the manufacturer's instructions. Briefly, 2.5µl of serum  
479 was incubated with Luminex MagPlex magnetic microspheres in a multiplex format conjugated  
480 to 19 full length human autoantigens (Cardiolipin, CENP B, H2a(F2A2) & H4 (F2A1), Jo-1,  
481 La/SS-B, Mi-2b, myeloperoxidase, proteinase-3, pyruvate dehydrogenase, RNP complex,  
482 Ro52/SS-A, Scl-34, Scl-70, Smith antigen, Thyroglobulin, Thyroid peroxidase,  
483 transglutaminase, U1-snRNP 68, whole histone) along with bovine serum albumin (BSA).  
484 Detection was undertaken using goat-anti-human IgG-RPE in a 96 well flat-bottomed plate and  
485 the plate was read in a Luminex xMAP 200 system. Raw fluorescence intensities (FI) were  
486 further processed in R (version 3.5.1) Non-specific BSA-bound FI was subtracted from  
487 background-corrected total FI for each antigen before log<sub>2</sub> transformation and thresholding.  
488 Outlier values (Q3+1.5\*IQR) in each distribution were defined as positive.

489

490 *Serum chemo/cytokine analysis*

491 Serum proteins were quantified using a validated electro chemiluminescent sandwich assay  
492 (Mesoscale Discovery VPLEX) quantification kit following the manufacturer's instructions.  
493 Briefly both sera and standard calibration controls were incubated with SULFO-tagged  
494 antibodies targeting IFN $\gamma$ , IL10, IL12p70, IL13, IL1 $\beta$ , IL2, IL4, IL6, IL8, TNF $\alpha$ , GC-CSF,  
495 IL1 $\alpha$ , IL12, IL15, IL16, IL17A, IL5, IL7, TNF $\beta$ , VEGF, MCP1, MCP4, Eotaxin, Eotaxin3,  
496 IP10, MDC, MIP-1 $\alpha$ , MIP-1 $\beta$ , TARC, IL17B, IL17C, IL17D, IL1RA, IL3, IL9, TSLP,  
497 VEGFA, VEGFC, VEGFD, VEGFR1/Flt1, PIGF, TIE2, FGF, ICAM1, VCAM1, SAA and  
498 CRP and read using an MSD MESO S600 instrument. Concentrations were calculated by  
499 comparison with an internal standard calibration curve fitted to a 4-parameter logistic model.  
500 Values below (19%) or above (0.0%) the reference range were imputed at the lower/upper  
501 limit of detection respectively. Association of each cytokine level with SARS-CoV-2  
502 neutralising antibody titre, neutralisation status (1/0) and age was undertaken using Kendall's  
503 Tau and Wilcoxon tests with FDR<5% considered significant.

504

505

506 *B Cell Receptor Repertoire Library Preparation*

507 PBMC were lysed and RNA extracted using Qiagen AllPrep® DNA/RNA mini kits and  
508 Allprep® DNA/RNA Micro kits according to the manufactures protocol. The RNA was  
509 quantified using a Qubit. B cell receptor repertoire libraries were generated for 52 COVID-19  
510 patients (58 samples) using as follows: 200ng of total RNA from PAXgenes (14ul volume)  
511 was combined with 1uL 10mM dNTP and 10uM reverse primer mix (2uL) and incubated for  
512 5 min at 70°C. The mixture was immediately placed on ice for 1 minute and then  
513 subsequently combined with 1uL DTT (0.1 M), 1uL SuperScriptIV (Thermo Fisher  
514 Scientific), 4ul SSIV Buffer (Thermo Fisher Scientific) and 1uL RNase inhibitor. The  
515 solution was incubated at 50 °C for 60 min followed by 15 min inactivation at 70 °C. cDNA  
516 was cleaned with AMPure XP beads and PCR-amplified with a 5' V-gene multiplex primer  
517 mix and 3' universal reverse primer using the KAPA protocol and the following thermal  
518 cycling conditions: 1cycle (95°C, 5min); 5cycles (98°C, 20s; 72°C, 30s); 5cycles (98°C, 15s;  
519 65°C, 30s; 72°C, 30s); 19cycles (98 °C, 15s; 60°C, 30s; 72°C, 30s); 1 step (72°C, 5 min).  
520 Sequencing libraries were prepared using Illumina protocols and sequenced using 300-bp  
521 paired-end sequencing on a MiSeq machine.

522

523 *Sequence analysis*

524 Raw reads were filtered for base quality using a median Phred score of  $\geq 32$   
525 (<http://sourceforge.net/projects/quasr/>). Forward and reverse reads were merged where a  
526 minimum 20bp identical overlapping region was present. Sequences were retained where over  
527 80% base sequence similarity was present between all sequences with the same barcode. The  
528 constant-region allele with highest sequence similarity was identified by 10-mer matching to  
529 the reference constant-region genes from the IMGT database. Sequences without complete  
530 reading frames and non-immunoglobulin sequences were removed and only reads with  
531 significant similarity to reference IGHV and J genes from the IMGT database using BLAST  
532 were retained. Immunoglobulin gene use and sequence annotation were performed in IMGT V-  
533 QUEST, and repertoire differences were performed by custom scripts in Python.

534

535 *Flow cytometry*

536

537 The following antibodies or staining reagents were purchased from BioLegend: CD19  
538 (SJ25C, 363028), CD3 (OKT3, 317328), CD11c (3.9, 301608), CD25 (M-A251, 356126),  
539 CD14 (M5E2,301836), and IgM (IgG1-k, 314524). CCR7 (150503, 561143) and IgG (G18-



540 145, 561297) were obtained from BD Bioscience, CD45RA (T6D11, 130-113-359) from  
541 Miltenyi Biotech, and CD8a (SK1, 48-0087-42) from eBiosciences. The LIVE/DEAD™  
542 Fixable Aqua Dead Cell Stain Kit was obtained from Invitrogen. Biotinylated Spike protein  
543 expressed and purified as previously described<sup>51</sup> was conjugated to Streptavidin R-  
544 Phycoerythrin (PJRS25-1), or Streptavidin APC obtained from Agilent Technologies.  
545 PBMCs were isolated from study participants and stored in liquid nitrogen. Aliquots  
546 containing 10<sup>7</sup> cells were thawed and stained in PBS containing 2mM EDTA at 4 °C with  
547 the above antibody panel and then transferred to 0.04% BSA in PBS. Events were acquired  
548 on a FACSAria Fusion (BD Biosciences). Analyses were carried out in FlowJo version  
549 10.7.1.

550

#### 551 *IFN $\gamma$ and IL2 FLUOROSpot T cell assays*

552 Peripheral blood mononuclear cells (PBMC) were isolated from the heparinized blood  
553 samples using Histopaque-1077 (Sigma-Aldrich) and SepMate-50 tubes (Stemcell  
554 Technologies). Frozen PBMCs were rapidly thawed and diluted into 10ml of TexMACS  
555 media (Miltenyi Biotech), centrifuged and resuspended in 10ml of fresh media with 10U/ml  
556 DNase (Benzonase, Merck-Millipore via Sigma-Aldrich), PBMCs were then incubated at  
557 37°C for 1h, followed by centrifugation and resuspension in fresh media supplemented with  
558 5% Human AB serum (Sigma Aldrich) before being counted. PBMCs were stained with 2ul  
559 of LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific) and live  
560 PBMC enumerated on the BD Accuri C6 flow cytometer.

561

#### 562 *Overlapping Spike SARS-CoV-2 peptide stimulation*

563 A peptide pool was generated using the following: 1. PepTivator SARS-CoV-2 Prot\_S  
564 containing the sequence domains aa 304-338, 421-475, 492-519, 683-707, 741-770, 785-802,  
565 and 885 – 1273 and S1 N-terminal S1 domain of the surface glycoprotein ("S") of SARS-  
566 Coronavirus 2 (GenBank MN908947.3, Protein QHD43416.1). 2. The PepTivator SARS-  
567 CoV-2 Prot\_S1 containing the aa sequence 1–692. The peptides used are 15aa amino acids  
568 with 11 amino acid overlaps.

569

570 1.0 to 2.5 x 10<sup>5</sup> PBMCs were incubated in pre-coated FluoroSpot<sup>FLEX</sup> plates (anti IFN $\gamma$  and  
571 IL2 capture antibodies Mabtech AB, Nacka Strand, Sweden)) in duplicate with spike peptide

572 pool mix as described above (specific for Wuhan-1, QHD43416.1) Spike SARS-CoV-2  
573 protein (Miltenyi Biotech) or a mixture of peptides specific for Cytomegalovirus, Epstein  
574 Barr virus and Influenza virus (CEF+, (Miltenyi Biotech)) (final peptide concentration  
575 manufactures recommendation 1 µg/ml/peptide, Miltenyi Biotech) in addition to an  
576 unstimulated (media only) and positive control mix (containing anti-CD3 (Mabtech AB) and  
577 Staphylococcus Enterotoxin B (SEB), (Sigma Aldrich)) at 37°C in a humidified  
578 CO<sub>2</sub> atmosphere for 42 hours. The cells and medium were then decanted from the plate and  
579 the assay developed following the manufacturer's instructions. Developed plates were read  
580 using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot  
581 v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany). Peptide specific  
582 frequencies were calculated by subtracting for background cytokine specific spots  
583 (unstimulated control) and expressed as SFU/Million PBMC.

584

585 *CD4 and CD8 depletion from PBMC for subsequent FLUOROSpot analysis*

586 Peripheral blood mononuclear cells were depleted of either CD4<sup>+</sup> or CD8<sup>+</sup> T cells by MACS  
587 using anti-CD4<sup>+</sup> or anti-CD8<sup>+</sup> direct beads (Miltenyi Biotec), according to manufacturer's  
588 instructions, and separated by using an AutoMACS Pro (Miltenyi Biotec). Efficiency of  
589 depletion was determined by staining cells with a CD3-FITC, CD4-PE, and CD8-  
590 PerCPCy5.5 antibody mix (all BioLegend) and analyzed by flow cytometry.

**Table 1: Characteristics of study participants**

	<b>&lt;80 years (N=80 or n/N)</b>	<b>≥80 years (N=60 or n/N)</b>	<b>P value</b>
<b>Female %</b>	60.0 (48)	38.3 (23)	0.01 <sup>a</sup>
<b>Median age (IQR) years</b>	45.5 (36.0-67.0)	83.0 (81.0-85.5)	-
<b>Sera GMT WT (95% CI)</b>			
<b>dose 1</b>	104.1 (69.7-155.2) <sup>b</sup>	48.2 (34.6-67.1) <sup>c</sup>	<0.0001 <sup>d</sup>
<b>dose 2</b>	886.1 (434.1-1808.7) <sup>e</sup>	598.3 (357.4-1001.5) <sup>f</sup>	0.53 <sup>d</sup>
<b>Serum ID50&lt;20 for WT %</b>			
<b>dose 1</b>	22.8 (18/79)	50.9 (30/59)	0.001 <sup>a</sup>
<b>dose 2</b>	0 (0/11) <sup>e</sup>	0 (0/21) <sup>f</sup>	-
<b>Prior SARS-CoV-2</b>	6.8 (5/74)	8.6 (5/58)	0.69

<sup>a</sup> Chi-square test, <sup>b</sup> neutralisation data unavailable for two individual, <sup>c</sup> neutralisation data unavailable for one individual, <sup>d</sup> Mann-Whitney test <sup>e</sup> neutralisation data available for 11 of 80, <sup>f</sup> neutralisation data available for 21 of 60, GMT- geometric mean titre, WT- wild type, ID50- (Inhibitory dilution) – the serum dilution achieving 50% neutralisation, CI-confidence interval.

**Table 2: Neutralisation in participants after the first dose of BNT162b2 vaccine against wild type and B.1.1.7 spike mutant pseudotyped viruses.**

	Number	Risk ID50<20	Unadjusted OR (95% CI)	P value	Adjusted OR* (95% CI)	P value
<b>WT</b>						
<b>Age group years</b>						
<80	78	23.1 (18/78)	1		1	
≥ 80	59	50.9 (30/59)	3.4 (1.7-7.2)	0.001	3.7 (1.7-8.1)	0.001
<b>Sex</b>						
Male	68	32.4 (22/68)	1		1	
Female	69	37.7 (26/69)	1.2 (0.6- 2.6)	0.52	1.4 (0.6-3.3)	0.39
<b>Time since dose 1 weeks</b>						
3-8	68	29.4 (20/68)	1		1	
9-12	69	40.6 (28/69)	1.6 (0.8-3.3)	0.17	1.6 (0.7-3.6)	0.25
<b>Previous COVID-19</b>						
No	121	35.5 (43/121)	1		1	
Yes	10	40.0 (4/100)	1.2 (0.3-4.5)	0.28	1.1 (0.3-4.6)	0.92
<b>B.1.1.7</b>						
<b>Age group years</b>						
<80	77	25.9 (20/77)	1		1	
≥ 80	58	60.3 (35/58)	4.3 (2.1-9.0)	<0.001	4.3 (2.0-9.3)	<0.001
<b>Sex</b>						
Male	67	43.3 (29/67)	1		1	
Female	68	38.2 (26/68)	0.8 (0.4-1.6)	0.55	1.2 (0.6-2.8)	0.59
<b>Time since dose 1 weeks</b>						
3-8	66	42.4 (28/66)	1		1	
9-12	69	39.1 (27/69)	0.9 (0.4-1.7)	0.70	0.7 (0.3-1.6)	0.41
<b>Previous COVID-19</b>						
No	120	41.7 (50/120)	1		1	
Yes	10	40.0 (4/10)	0.9 (0.3-3.5)	0.92	0.9 (0.2-3.6)	0.88

\* Mutually adjusted for other variables in the table. WT- wild type, B.1.1.7- Spike mutant with N501Y, A570D,  $\Delta$ H69/V70,  $\Delta$ 144/145, P681H, T716I, S982A and D1118H, OR- odds ratio, ID50- (Inhibitory dilution) – the serum dilution achieving 50% neutralisation, ns- non-significant, CI-confidence interval.

## **The CITIID-NIHR BioResource COVID-19 Collaboration**

### **Principal Investigators**

Stephen Baker<sup>2, 3</sup>, Gordon Dougan<sup>2, 3</sup>, Christoph Hess<sup>2,3,28,29</sup>, Nathalie Kingston<sup>22, 12</sup>, Paul J. Lehner<sup>2, 3</sup>, Paul A. Lyons<sup>2, 3</sup>, Nicholas J. Matheson<sup>2, 3</sup>, Willem H. Owehand<sup>22</sup>, Caroline Saunders<sup>21</sup>, Charlotte Summers<sup>3,26,27,30</sup>, James E.D. Thaventhiran<sup>2, 3, 24</sup>, Mark Toshner<sup>3, 26, 27</sup>, Michael P. Weekes<sup>2</sup>, Patrick Maxwell<sup>22,30</sup>, Ashley Shaw<sup>30</sup>

### **CRF and Volunteer Research Nurses**

Ashlea Bucke<sup>21</sup>, Jo Calder<sup>21</sup>, Laura Canna<sup>21</sup>, Jason Domingo<sup>21</sup>, Anne Elmer<sup>21</sup>, Stewart Fuller<sup>21</sup>, Julie Harris<sup>43</sup>, Sarah Hewitt<sup>21</sup>, Jane Kennet<sup>21</sup>, Sherly Jose<sup>21</sup>, Jenny Kourampa<sup>21</sup>, Anne Meadows<sup>21</sup>, Criona O'Brien<sup>43</sup>, Jane Price<sup>21</sup>, Cherry Publico<sup>21</sup>, Rebecca Rastall<sup>21</sup>, Carla Ribeiro<sup>21</sup>, Jane Rowlands<sup>21</sup>, Valentina Ruffolo<sup>21</sup>, Hugo Tordesillas<sup>21</sup>,

### **Sample Logistics**

Ben Bullman<sup>2</sup>, Benjamin J. Dunmore<sup>3</sup>, Stuart Fawke<sup>32</sup>, Stefan Gräf<sup>3,22,12</sup>, Josh Hodgson<sup>3</sup>, Christopher Huang<sup>3</sup>, Kelvin Hunter<sup>2, 3</sup>, Emma Jones<sup>31</sup>, Ekaterina Legchenko<sup>3</sup>, Cecilia Matara<sup>3</sup>, Jennifer Martin<sup>3</sup>, Federica Mescia<sup>2, 3</sup>, Ciara O'Donnell<sup>3</sup>, Linda Pointon<sup>3</sup>, Nicole Pond<sup>2, 3</sup>, Joy Shih<sup>3</sup>, Rachel Sutcliffe<sup>3</sup>, Tobias Tilly<sup>3</sup>, Carmen Treacy<sup>3</sup>, Zhen Tong<sup>3</sup>, Jennifer Wood<sup>3</sup>, Marta Wylot<sup>38</sup>,

### **Sample Processing and Data Acquisition**

Laura Bergamaschi<sup>2, 3</sup>, Ariana Betancourt<sup>2, 3</sup>, Georgie Bower<sup>2, 3</sup>, Chiara Cossetti<sup>2, 3</sup>, Alok De Sa<sup>3</sup>, Madeline Epping<sup>2, 3</sup>, Stuart Fawke<sup>32</sup>, Nick Gleadall<sup>22</sup>, Richard Grenfell<sup>33</sup>, Andrew Hinch<sup>2,3</sup>, Oisín Huhn<sup>34</sup>, Sarah Jackson<sup>3</sup>, Isobel Jarvis<sup>3</sup>, Ben Krishna<sup>3</sup>, Daniel Lewis<sup>3</sup>, Joe Marsden<sup>3</sup>, Francesca Nice<sup>41</sup>, Georgina Okecha<sup>3</sup>, Ommar Omarjee<sup>3</sup>, Marianne Perera<sup>3</sup>, Martin Potts<sup>3</sup>, Nathan Richoz<sup>3</sup>, Veronika Romashova<sup>2,3</sup>, Natalia Savinykh Yarkoni<sup>3</sup>, Rahul Sharma<sup>3</sup>, Luca Stefanucci<sup>22</sup>, Jonathan Stephens<sup>22</sup>, Mateusz Strezlecki<sup>33</sup>, Lori Turner<sup>2, 3</sup>,

### **Clinical Data Collection**

Eckart M.D.D. De Bie<sup>3</sup>, Katherine Bunclark<sup>3</sup>, Masa Josipovic<sup>42</sup>, Michael Mackay<sup>3</sup>, Federica Mescia<sup>2,3</sup>, Alice Michael<sup>27</sup>, Sabrina Rossi<sup>37</sup>, Mayurun Selvan<sup>3</sup>, Sarah Spencer<sup>15</sup>, Cissy Yong<sup>37</sup>

### **Royal Papworth Hospital ICU**

Ali Ansari<sup>27</sup>, Alice Michael<sup>27</sup>, Lucy Mwaura<sup>27</sup>, Caroline Patterson<sup>27</sup>, Gary Polwarth<sup>27</sup>

### **Addenbrooke's Hospital ICU**

Petra Polgarova<sup>30</sup>, Giovanni di Stefano<sup>30</sup>

### **Cambridge and Peterborough Foundation Trust**

Codie Fahey<sup>36</sup>, Rachel Michel<sup>36</sup>

### **ANPC and Centre for Molecular Medicine and Innovative Therapeutics**

Sze-How Bong<sup>23</sup>, Jerome D. Coudert<sup>35</sup>, Elaine Holmes<sup>39</sup>

### **NIHR BioResource**

John Allison<sup>22,12</sup>, Helen Butcher<sup>12,40</sup>, Daniela Caputo<sup>12,40</sup>, Debbie Clapham-Riley<sup>12,40</sup>, Eleanor Dewhurst<sup>12,40</sup>, Anita Furlong<sup>12,40</sup>, Barbara Graves<sup>12,40</sup>, Jennifer Gray<sup>12,40</sup>, Tasmin Ivers<sup>12,40</sup>, Mary Kasanicki<sup>12,30</sup>, Emma Le Gresley<sup>12,40</sup>, Rachel Linger<sup>12,40</sup>, Sarah Meloy<sup>12,40</sup>, Francesca Muldoon<sup>12,40</sup>, Nigel Ovington<sup>22,12</sup>, Sofia Papadia<sup>12,40</sup>, Isabel Phelan<sup>12,40</sup>, Hannah Stark<sup>12,40</sup>, Kathleen E Stirrups<sup>22,12</sup>, Paul Townsend<sup>22,12</sup>, Neil Walker<sup>22,12</sup>, Jennifer Webster<sup>12,40</sup>.

21. Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
22. University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
23. Australian National Phenome Centre, Murdoch University, Murdoch, Western Australia WA 6150, Australia
24. MRC Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge CB2 1QR, UK
25. R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands
26. Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
27. Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
28. Department of Biomedicine, University and University Hospital Basel, 4031Basel, Switzerland
29. Botnar Research Centre for Child Health (BRCCH) University Basel & ETH Zurich, 4058 Basel, Switzerland
30. Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
31. Department of Veterinary Medicine, Madingley Road, Cambridge, CB3 0ES, UK
32. Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK
33. Cancer Research UK, Cambridge Institute, University of Cambridge CB2 0RE, UK
34. Department of Obstetrics & Gynaecology, The Rosie Maternity Hospital, Robinson Way, Cambridge CB2 0SW, UK
35. Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA, Australia
36. Cambridge and Peterborough Foundation Trust, Fulbourn Hospital, Fulbourn, Cambridge CB21 5EF, UK
37. Department of Surgery, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
38. Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK
39. Centre of Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, WA 6150, Australia

40. Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

## References

- 1 Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *New England Journal of Medicine* **383**, 2439-2450, doi:10.1056/NEJMoa2027906 (2020).
- 2 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 3 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2020).
- 4 Houry, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine*, doi:10.1038/s41591-021-01377-8 (2021).
- 5 Israelow, B. *et al.* Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. *bioRxiv*, 2021.2005.2019.444825, doi:10.1101/2021.05.19.444825 (2021).
- 6 Health, D. o. *Briefing on rescheduling of second doses of the Pfizer/BioNTech Covid-19 vaccine*, <<https://www.health-ni.gov.uk/news/briefing-rescheduling-second-doses-pfizerbiontech-covid-19-vaccine>> (2021).
- 7 Docherty, A. B. *et al.* Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* **369**, m1985, doi:10.1136/bmj.m1985 (2020).
- 8 Volz, E. *et al.* Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*, doi:10.1038/s41586-021-03470-x (2021).
- 9 Collier, D. A. *et al.* SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. *Nature* **593**, 136-141, doi:10.1101/2021.01.19.21249840 (2021).
- 10 Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med*, doi:10.1056/NEJMoa2102214 (2021).
- 11 Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020.2006.2008.140871, doi:10.1101/2020.06.08.140871 %J bioRxiv (2020).
- 12 Raybould, M. I. J., Kovaltsuk, A., Marks, C. & Deane, C. M. CoV-AbDab: the coronavirus antibody database. *Bioinformatics* **37**, 734-735, doi:10.1093/bioinformatics/btaa739 (2020).
- 13 Mercado, N. B. *et al.* Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature* **586**, 583-588, doi:10.1038/s41586-020-2607-z (2020).
- 14 McMahan, K. *et al.* Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature* **590**, 630-634, doi:10.1038/s41586-020-03041-6 (2021).
- 15 Merani, S., Pawelec, G., Kuchel, G. A. & McElhaney, J. E. Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. *Front Immunol* **8**, 784, doi:10.3389/fimmu.2017.00784 (2017).
- 16 Kadambari, S., Klenerman, P. & Pollard, A. J. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. *Rev Med Virol* **30**, e2144, doi:10.1002/rmv.2144 (2020).




- 17 Ray, D. & Yung, R. Immune senescence, epigenetics and autoimmunity. *Clin Immunol* **196**, 59-63, doi:10.1016/j.clim.2018.04.002 (2018).
- 18 Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. *Science* **369**, 256-257, doi:10.1126/science.abb0762 (2020).
- 19 Haq, K. & McElhaney, J. E. Immunosenescence: Influenza vaccination and the elderly. *Curr Opin Immunol* **29**, 38-42, doi:10.1016/j.coi.2014.03.008 (2014).
- 20 Izurieta, H. S. *et al.* Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. *Lancet Infect Dis* **15**, 293-300, doi:10.1016/S1473-3099(14)71087-4 (2015).
- 21 Libster, R. *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *New England Journal of Medicine*, doi:10.1056/NEJMoa2033700 (2021).
- 22 Madhi, S. A. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. *medRxiv*, 2021.2002.2010.21251247, doi:10.1101/2021.02.10.21251247 (2021).
- 23 Anderson, E. J. *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine* **383**, 2427-2438, doi:10.1056/NEJMoa2028436 (2020).
- 24 Li, J. *et al.* Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. *Nature medicine*, doi:10.1038/s41591-021-01330-9 (2021).
- 25 Silva-Cayetano, A. *et al.* A Booster Dose Enhances Immunogenicity of the COVID-19 Vaccine Candidate ChAdOx1 nCoV-19 in Aged Mice. *Med (N Y)*, doi:10.1016/j.medj.2020.12.006 (2020).
- 26 Docherty, A. B. *et al.* Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* **369**, m1985, doi:10.1136/bmj.m1985 (2020).
- 27 Garcia-Beltran, W. F. *et al.* Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* **184**, 2523, doi:10.1016/j.cell.2021.04.006 (2021).
- 28 Helen Ward *et al.* REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. (2021).
- 29 Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881-891, doi:10.1016/S0140-6736(21)00432-3 (2021).
- 30 Bernal, J. L. *et al.* Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. *medRxiv*, 2021.2003.2001.21252652, doi:10.1101/2021.03.01.21252652 (2021).
- 31 Vasileiou, E. S., Colin & Robertson, Chris & Shi, Ting & Kerr, Steven & Agrawal, Utkarsh & Akbari, Ashley & Bedston, Stuart & Beggs, Jillian & Bradley, Declan & Chuter, Antony & Lusignan, Simon & Docherty, Annemarie & Ford, David & Hobbs, FD & Joy, Mark & Katikireddi, Srinivasa & Marple, James & McCowan, Colin & Sheikh, Aziz. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. (2021).

- 32 Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine*, doi:10.1056/NEJMc2104974 (2021).
- 33 Peng, Y. *et al.* Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature Immunology* **21**, 1336-1345, doi:10.1038/s41590-020-0782-6 (2020).
- 34 Zuo, J. *et al.* Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. *Nature Immunology*, doi:10.1038/s41590-021-00902-8 (2021).
- 35 Ewer, K. J. *et al.* T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nature Medicine* **27**, 270-278, doi:10.1038/s41591-020-01194-5 (2021).
- 36 Zhu, F. C. *et al.* Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* **396**, 479-488, doi:10.1016/s0140-6736(20)31605-6 (2020).
- 37 Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* **586**, 594-599, doi:10.1038/s41586-020-2814-7 (2020).
- 38 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *New England Journal of Medicine* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
- 39 Barrett, J. R. *et al.* Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. *Nature medicine* **27**, 279-288, doi:10.1038/s41591-020-01179-4 (2021).
- 40 Lederer, K. *et al.* SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. *Immunity* **53**, 1281-1295 e1285, doi:10.1016/j.immuni.2020.11.009 (2020).
- 41 Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. *J Allergy Clin Immunol* **145**, 1309-1321, doi:10.1016/j.jaci.2020.03.017 (2020).
- 42 Bentebibel, S. E. *et al.* ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination. *Sci Rep* **6**, 26494, doi:10.1038/srep26494 (2016).
- 43 Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. & Leshem, E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *Lancet*, doi:10.1016/S0140-6736(21)00448-7 (2021).
- 44 Collier, D. A. *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited neutralizing antibodies. *Nature* In press, doi:10.1101/2021.01.19.21249840 (2021).
- 45 Tegally, H. *et al.* Major new lineages of SARS-CoV-2 emerge and spread in South Africa during lockdown. *medRxiv*, 2020.2010.2028.20221143, doi:10.1101/2020.10.28.20221143 (2020).
- 46 Kemp, S. *et al.* Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70. *bioRxiv*, 2020.2012.2014.422555, doi:10.1101/2020.12.14.422555 (2021).
- 47 Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv*, 2020.2012.2030.20249034, doi:10.1101/2020.12.30.20249034 (2021).
- 48 Kemp, S. A. *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature*, doi:10.1038/s41586-021-03291-y (2021).


- 49 Mlcochova, P. *et al.* Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G Spike Variant. *Cell Rep Med*, 100099, doi:10.1016/j.xcrm.2020.100099 (2020).
- 50 Xiong, X. *et al.* A thermostable, closed SARS-CoV-2 spike protein trimer. *Nature Structural & Molecular Biology* **27**, 934-941, doi:10.1038/s41594-020-0478-5 (2020).
- 51 Graham, C. *et al.* Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. *Immunity*, doi:10.1016/j.immuni.2021.03.023 (2021).

Supplementary tables


**Supplementary Table 2: Neutralisation in participants after the first dose of BNT162b2 vaccine against wild type and B.1.1.7, B.1.351 and P.1 spike mutant pseudotyped viruses.**




**Figure 1. SARS-CoV-2 neutralisation by Pfizer BNT162b2 vaccine sera.** **a.** Proportion of individuals with detectable serum neutralisation of PV after the first dose of Pfizer BNT162b2 vaccine by age. Cut off for serum neutralisation is the inhibitory dilution at which 50% inhibition of infection is achieved, ID50 of 20. The probability is bound by 95% confidence interval. **b.** SARS-CoV-2 PV neutralisation by Pfizer BNT162b2 first and second dose vaccine sera. Data are shown as mean ID50 values for individuals after Dose 1 (n=138) and after Dose 2 (n=32). Geometric mean with s.d is shown. Each point is a mean of technical replicates from two experiment repeats. **c.** Serum neutralisation of PV after Dose 1 (blue) or dose 2 (red) by age-group <80 years (n=79), ≥80 years (n=59). **c.** Neutralisation curves for serum from six individuals with reduced responses after first dose (blue) and increased neutralization activity after second dose (red) of Pfizer BNT162b2 vaccine against pseudovirus expressing wild type Spike (D614G). Neutralisation curves are means of technical replicates, plotted with error bars representing standard error of mean. **d.** diagram depicting spike mutations in variants of concern, along with number of sequences in GISAID **e.** Impact of SARS-CoV-2 variants of concern on neutralisation by Pfizer BNT162b2 dose 1 vaccine sera. WT (n=138), B.1.1.7 (n=135) Spike mutant B.1.351 (n=82) Spike mutant, P.1 (n=82). Geometric mean titre and s.d are shown. **f.** The proportion of participant vaccine sera with undetectable neutralisation of WT and Spike mutant (ID50 < 1 in 20 dilution of sera). WT (n=138), B.1.1.7 (n=135) Spike mutant; B.1.351 (n=82) spike mutant, P.1 (n=82) spike mutant. GMT with s.d are representative of two independent experiments each with two technical repeats. Mann-Whitney test was used for unpaired comparisons and Wilcoxon matched-pairs signed rank test for paired comparisons. p-values \* <0.05, \*\* <0.01, \*\*\*\* <0.0001, ns not significant, HS – human AB serum control, r – Pearson’s correlation coefficient, β – slope/regression coefficient, p p-value. Bonferroni adjustment was made for multiple comparisons in linear regression.




**Figure 2: SARS-CoV-2 spike binding antibody responses and SARS-CoV-2 spike specific B memory cells in blood following vaccination with Pfizer BNT162b2 vaccine.** **a.** Anti-Spike IgG- total and subclasses after first and second dose of vaccine compared to individuals with prior infection. **b.** Correlation between anti-Spike IgG binding antibody responses after first dose vaccine and age (n=134). **c.** Anti-Spike IgG subclass responses to first dose vaccine stratified by age <80 and ≥80 years. **d.** Correlations between anti-Spike IgG (n=134) binding antibody responses and neutralisation by vaccine sera against SARS-CoV-2 in a spike lentiviral pseudotyping assay expressing wild type Spike (D614G). **e.** CD19+ B memory (as % of PBMC) and SARS-CoV-2 spike specific B memory CD19+ IgG+ IgM- cells (as % of memory B cells) from FACS sorted PBMC. (n=16 above 80 and n=16 below 80 stratified by neutralizing response after first dose, n=8 in each category) MFI – mean fluorescence intensity. S – Spike, N – nucleocapsid, RBD – Spike receptor binding domain. Mann-whitney test was used for unpaired comparisons. p-values \* <0.05, \*\*<0.01, \*\*\*<0.001, \*\*\*\*<0.0001, ns- not significant HS – human AB serum control, Scatter plots show linear correlation line bounded by 95% confidence interval, r– Pearson’s correlation coefficient, p- P value, β slope/regression coefficient.



**Figure 3: B cell repertoire following vaccination with first dose of Pfizer BNT162b2 vaccine. a.** Boxplots showing Isotype usage according to unique VDJ sequence comparing participants <80 vs > 80 years old and association with neutralisation of spike pseudotyped virus. Neutralisation cut-off for 50% neutralisation was set at 20. **b.** Heat map showing V gene usage, comparing under 80 year olds with 80 year olds and older. A Benjamini Hochberg FDR correction was used, setting the threshold at 0.1. **B cell somatic hypermutation and BCR diversity following vaccination with first dose of Pfizer BNT162b2 vaccine. c.** Boxplots showing mean somatic hypermutation comparing <80 year olds with > 80 year old participants, grouped according to isotype class **d.** Correlation between somatic hypermutation in class-switched isotypes and IC50. **e.** Correlation between somatic hypermutation in IgHA BCR and IC50. **f.** Diversity Indices. The inverse is depicted for the Simpson's index is normalised. **g.** BCR comparison with public clones known to be associated with SARS-CoV-2 neutralisation via the CoV-AbDab database (Raybould et al., 2020). Convergent clones were annotated with the same IGHV and IGHJ segments, had the same CDR-H3 region length and were clustered based on 85% CDR-H3 sequence amino acid homology. A cluster was considered convergent with the CoV-AbDab database if it contained sequences from post-vaccinated individuals and from the database.







**Figure 4: T cell responses to Pfizer BNT162b2 vaccine after the first and second doses of vaccine.** FluoroSpot analysis by age for **a**. IFN $\gamma$  and **b**. IL-2 T cell responses specific to SARS-CoV-2 Spike protein peptide pool following PBMC stimulation. **c**. FluoroSpot interferon gamma PBMC responses to peptide pool of Cytomegalovirus, Epstein Barr virus and Influenza virus (CEF) Response from unexposed stored PBMC 2014-2016  $n=20$ ,  $<80$ yo ( $n=46$ ) and  $>80$ yo ( $n=35$ ) three weeks after the first doses of Pfizer BNT162b2 vaccine. FluoroSpot analysis for **d**. IFN $\gamma$  and **e**. IL-2 T cell responses specific to SARS-CoV-2 Spike protein peptide pool following PBMC stimulation of a cohort of unexposed (stored PBMC 2014-2016  $n=20$ ) and vaccinees  $<80$ yo IFN $\gamma$  ( $n=46$ ), IL-2 ( $n=44$ ) and  $>80$ yo IFN $\gamma$  ( $n=35$ ), IL-2 ( $n=27$ ) three weeks or more after the first doses of Pfizer BNT162b2 vaccine. **f**. FluoroSpot analysis for IFN $\gamma$  and **g**. IL-2 T cell responses specific to SARS-CoV-2 Spike protein peptide pool following PBMC stimulation of a cohort of infected ( $n=46$ ), unexposed ( $n=20$ ) and all vaccinees three weeks or more after the first doses IFN $\gamma$  ( $n=77$ ), IL-2 ( $n=64$ ) and three weeks after second IFN $\gamma$  and IL-2 ( $n=39$ ) of Pfizer BNT162b2 vaccine. **h**. FluoroSpot analysis for IFN $\gamma$  and **i**. IL-2 T cell responses specific to SARS-CoV-2 Spike protein peptide pool following PBMC stimulation of a cohort of unexposed ( $n=20$ ) and vaccinees  $<80$ yo IFN $\gamma$  ( $n=46$ ), IL-2 ( $n=45$ ) and  $>80$ yo IFN $\gamma$  ( $n=31$ ), IL-2 ( $n=19$ ) three weeks after the first doses and  $<80$ yo IFN $\gamma$  ( $n=15$ ), IL-2 ( $n=15$ ) and  $>80$ yo IFN $\gamma$  ( $n=24$ ), IL-2 ( $n=24$ ) three weeks after second dose of Pfizer BNT162b2 vaccine. FluoroSpot analysis for **j**. IFN $\gamma$  and **k**. IL-2 CD4 and CD8 T cell responses specific to SARS-CoV-2 Spike protein peptide pool following stimulation following column based PBMC separation. Mann-whitney test was used for unpaired comparisons and Wilcoxon matched-pairs signed rank test for paired comparisons.  $p$ -values  $*$   $< 0.05$ , ns not significant Mann-whitney test was used for unpaired comparisons and Wilcoxon matched-pairs signed rank test for paired comparisons.  $p$ -values  $**$   $< 0.01$ ,  $***$   $< 0.001$ , ns not significant.




Extended data Figure 1: study flow diagram for samples and analyses






**Extended Data Figure 2. SARS-CoV-2 neutralisation by Pfizer BNT162b2 vaccine sera with age.** **a.** Linear correlation of live virus neutralization with SARS-CoV-2 spike pseudotyped virus (PV) neutralization for 13 sera from individuals vaccinated with Pfizer vaccine. Linear regression line plotted bounded by 95% confidence interval. **b** SARS-CoV-2 PV neutralisation by Pfizer BNT162b2 vaccine sera following first dose in individuals ( $n=140$ ) with time of sampling since dose shown on x axis. Red dots are individuals 80 years old and above, blue dots are those below 80 years old. **c.** Correlation of SARS-CoV-2 neutralisation by Pfizer BNT162b2 vaccine sera with age. Serum neutralisation of Spike (D614G) pseudotyped lentiviral particles (inhibitory dilution at which 50% inhibition of infection is achieved, ID<sub>50</sub>) after Dose 1 (A  $n=138$ ) or dose 2 (B  $n=32$ ) by age. Linear regression line plotted bounded by 95% confidence interval.  $r$ – Pearson’s correlation coefficient,  $\beta$  slope/regression coefficient,  $p$  p-value. Bonferroni adjustment was made for multiple comparisons  $n$  linear regression. **D.** ID<sub>50</sub> against WT (D614G) pseudotyped virus (PV) following the second dose of vaccine stratified by interval between vaccine doses [3 weeks ( $n=21$ ) and 12 weeks ( $n=11$ )]. Geometric mean titre with s.d. Mann-whitney test.


a




b



c





d




### Extended Data Figure 3. Binding IgG and IgA spike antibody responses following BNT162b2 vaccination a.

Correlations between serum binding IgG subclass 1-4 antibody responses following vaccination with first dose of Pfizer BNT162b2 vaccine and age in years (n=133). **b.** Correlations between serum binding IgG subclass 1-4 antibody responses following vaccination with first dose of Pfizer BNT162b2 vaccine and serum neutralization using a pseudotyped viral (PV) system (n=133). **c.** IgA responses to S, N, RBD post first dose (light green, n=133) and second dose (dark green, n=21) compared to individuals with prior infection (red, n=18) and negative controls (grey, n=18) at serum dilutions 1 in 100. **d.** Correlations between serum binding IgA spike antibody responses following vaccination with first dose of Pfizer BNT162b2 vaccine and age in years and serum neutralization using a pseudotyped viral system (n=133). MFI- mean fluorescence intensity ID50 – inhibitory dilution required to achieve 50% inhibition of viral infection. r pearson’s correlation coefficient,  $\beta$  slope/regression coefficient, p p-value. Bonferroni adjustment was made for multiple comparisons. Spike proteins tested are Wuhan-1 with D614G.




**Extended Data Figure 4: Peripheral blood Lymphocyte subsets following first dose BNT162b vaccination.** PBMC were FACS sorted (n=16 above 80 and n=16 below 80). **a.** Gating strategy for flow cytometry analysis of human immune cells post BNT162b vaccination. **b** data for indicated sorted cell subsets stratified by neutralizing response after first dose, n=8 in each category). NK cell CD3- CD14- CD19 - and CD56 positive cells


## a Isotype usage



## b Vgene Proportions




## c Diversity




**Extended Data Figure 5. B cell repertoire following vaccination with first dose of Pfizer BNT162b2 vaccine. a.** Isotype usage according to unique VDJ sequence comparing under 80 year olds with 80 year olds and older. **b.** Boxplots showing V gene usage as a proportion, comparing neutralisation of spike pseudotyped virus. Neutralisation cut-off for 50% neutralisation was set at 20. **c.** Diversity Indices comparing under 80 year olds with 80 year olds and older. The inverse is depicted for the Simpson's index and the Shannon-Weiner index is normalised.





a



b




**Extended Data Figure 6. Correlation between T cell responses against SARS-CoV-2 Spike peptide pool and serum neutralisation of Spike (D614G) pseudotyped lentiviral particles (inhibitory dilution at which 50% inhibition of infection is achieved, ID50). a,b.** Correlation of IFN $\gamma$  (n=79) and IL2 (n=69) FluoroSpot and ID50 after first dose. SFU: spot forming units. Linear regression line with 95% confidence intervals are plotted.  $r$ : Pearson's correlation coefficient.  $p$  value indicated and  $b$  the slope or coefficient. Bonferroni adjustment was made for multiple comparisons.




**Extended Data Figure 7. Human cytomegalovirus serostatus, T cell responses and serum neutralisation of Spike (D614G) pseudotyped lentiviral particles (inhibitory dilution at which 50% inhibition of infection is achieved, ID50) to Pfizer BNT162b2 vaccine after the first dose of vaccine. Dose 1.** **a.** (n=72) HCMV serostatus by <80 and ≥80 year age groups, HCMV positive (blue), HCMV negative (pink). **b** IFN $\gamma$  (n=72) and **c.** IL2 (n=64) FluoroSpot response after the first dose. **d.** Inhibitory dilution at which 50% inhibition of infection after the first dose. SFU- spot forming units. ID50-inhibitory dilution at which 50% inhibition of infection is achieved. HCMC- Human cytomegalovirus., CEF- Cytomegalovirus Epstein Barr virus, Influenza virus


a




b




c



d



e



### Extended Data Figure 8: Autoantibodies and inflammatory markers in participants receiving at least one dose of the Pfizer BNT162b2 vaccine and relationship to SARS-CoV-2 spike specific IgG and SARS-CoV-2 PV neutralisation. (n=101).

**a.** Heatmap of log2 transformed fluorescence intensity (FI) of 19 autoantibodies, positive (red), negative (blue). **b.** Age in years by anti-MPO antibody positive (red) or negative (blue) status. Plotted is the mean age and s.d. **c.** (n=100) IgG subclass responses to Spike post first dose Pfizer BNT162b2 vaccine comparing individuals with anti-MPO antibody positive (red) or negative (blue) status. **d.** GMT with s.d of first dose Pfizer BNT162b2 vaccine sera against wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudotyped viruses by anti-MPO antibody positive (red) or negative (blue) status. Ab+ antibody positive, Ab- antibody negative, MPO- myeloperoxidase, P – p-value, WT- wild type, B.1.1.7 Spike mutant with N501Y, A570D,  $\Delta$ H69/V70,  $\Delta$ 144/145, P681H, T716I, S982A and D1118H. **e.** Nonparametric rank correlation (Kendall's tau-b) of wild type (WT), variant (B.1.17) and age (>80 years) against each of 53 cyto/chemokines. Heatmaps illustrate Tau-b statistic (left) and significance (right,  $-\log_{10}FDR$ ).

	Number	Risk ID50<20	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
<b>WT</b>						
<b>Age group years</b>						
<80	55	25.5 (14/55)	1		1	
≥ 80	27	48.2 (13/27)	2.7 (1.3-7.2)	0.04	2.4 (0.8-6.8)	0.06
<b>Sex</b>						
Male	33	33.3 (11/33)	1		1	
Female	49	32.7 (16/49)	1.0 (0.4-2.5)	0.95	1.0 (0.3-3.2)	0.94
<b>Time since dose 1 weeks</b>						
3-8	28	25.0 (7/28)	1		1	
9-12	54	37.0 (20/54)	1.8 (0.6-4.9)	0.27	1.9 (0.6-6.0)	0.25
<b>Previous COVID-19</b>						
No	72	33.3 (24/72)	1		1	
Yes	6	50.0 (3/6)	1.7 (0.4-10.7)	0.42	1.8 (0.3-10.4)	0.53
<b>B.1.1351</b>						
<b>Age group years</b>						
<80	55	69.1 (38/55)	1		1	
≥ 80	27	81.5 (22/27)	2.0 (0.6- 6.1)	0.24	1.7 (0.5-5.7)	0.41
<b>Sex</b>						
Male	33	72.7 (24/33)	1		1	
Female	49	73.5 (36/49)	1.0 (0.4-2.8)	0.94	1.3 (0.4- 4.4)	0.66
<b>Time since dose 1 weeks</b>						
3-8	28	75.0 (21/28)	1		1	
9-12	54	72.2 (39/54)	0.9 (0.3-2.5)	0.79	1.0 (0.3-3.4)	0.94
<b>Previous COVID-19</b>						
No	72	77.8 (56/72)	1		1	
Yes	6	66.7 (4/6)	0.6 (0.1- 3.4)	0.54	0.5 (0.1-3.3)	0.51
<b>P.1</b>						
<b>Age group years</b>						
<80	55	52.7 (29/55)	1		1	
≥ 80	27	88.9 (24/27)	7.2 (1.9-26.6)	0.003	6.7 (1.7- 26.3)	0.008
<b>Sex</b>						
Male	33	66.7 (22/33)	1		1	
Female	49	63.3 (31/49)	0.9 (0.3-2.2)	0.75	1.2 (0.4-4.0)	0.71
<b>Time since dose 1 weeks</b>						
3-8	28	60.7 (17/28)	1		1	



<b>9-12</b>	54	66.7 (36/54)	1.3 (0.5-3.3)	0.59	1.5 (0.5-4.7)	0.46
<b>Previous COVID-19</b>						
<b>No</b>	72	68.1 (49/72)	1		1	
<b>Yes</b>	6	66.7 (4/6)	0.9 (0.2-5.5)	0.94	0.8 (0.1-5.5)	0.77